833 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by SkyOak Wealth LLC

SkyOak Wealth LLC bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, Holdings Channel reports. The firm bought 833 shares of the company’s stock, valued at approximately $277,000.

Other institutional investors also recently added to or reduced their stakes in the company. Iron Triangle Partners LP bought a new stake in shares of Medpace in the 3rd quarter worth $64,371,000. Wellington Management Group LLP grew its holdings in Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after acquiring an additional 109,886 shares during the period. DF Dent & Co. Inc. raised its position in Medpace by 189.9% in the third quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock worth $53,841,000 after acquiring an additional 105,659 shares in the last quarter. Argent Capital Management LLC lifted its holdings in Medpace by 431.5% in the 3rd quarter. Argent Capital Management LLC now owns 91,732 shares of the company’s stock valued at $30,620,000 after acquiring an additional 74,473 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec bought a new position in shares of Medpace during the 3rd quarter valued at about $23,321,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MEDP. TD Cowen decreased their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Redburn Atlantic began coverage on Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 target price on the stock. Robert W. Baird upped their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Stock Down 0.3 %

Shares of MEDP stock opened at $349.15 on Monday. The company has a market capitalization of $10.85 billion, a P/E ratio of 30.57, a P/E/G ratio of 1.79 and a beta of 1.36. Medpace Holdings, Inc. has a 12-month low of $286.76 and a 12-month high of $459.77. The firm has a 50-day moving average price of $342.50 and a 200 day moving average price of $351.96.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.